Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6434

Provisional Schedule

Committee meeting 12 March 2025
Expected publication 30 April 2025

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Stakeholders

Companies sponsors Pfizer (lorlatinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups ALK Positive UK
  Oncogene Cancer Research
  Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  Cancer Research UK
  Royal College of Physicians
Comparator companies Roche (alectinib)
  Takeda (brigatinib)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
10 July 2024 Invitation to participate
10 July 2024 In progress. Invitation to Participate
18 June 2024 - 02 July 2024 Review proposal consultation
25 June 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual